Adding durvalumab to perioperative FLOT improves gastric cancer outcomes Summary Adding the immunotherapy drug durvalumab to the standard perioperative chemotherapy regimen FLOT significantly improves outcomes for patients with resectable gastric or gastroesophageal junction cancer. The Read More